Neumora Overview
- Founded
- 2019
- Status
- Private
- Employees
- 90
- Latest Deal Type
- Series A2
- Latest Deal Amount
- $100M
- Investors
- 16
Neumora General Information
Description
Developer of a clinical-stage biotechnology company designed to pioneer precision medicines for brain diseases through the integration of data science and neuroscience. The company offers a precision neuroscience platform that cuts through brain disease heterogeneity to match the right patient populations to targeted therapeutics, thereby helping doctors with more precise treatments for specific groups of patients, and helps researchers design better studies to evaluate them.
Contact Information
Website
www.neumoratx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Decision/Risk Analysis
Biotechnology
Primary Office
- 65 Grove Street
- Suite 102
- Watertown, MA 02472
- United States
Neumora Timeline
Neumora Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A2) | 07-Oct-2021 | $100M | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 1. Early Stage VC (Series A) | 07-Oct-2021 | 00000 | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
Neumora Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | 000,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
| Series A1 | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
Neumora Executive Team (13)
Neumora Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Kristina Burow | Self | Co-Founder & Board Member | 000 0000 |
| Matthew Fust | Self | Board Member | 000 0000 |
| Maykin Ho Ph.D | Self | Board Member | 000 0000 |
| Paul Berns | Self | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
| Robert Nelsen | Self | Co-Founder & Board Member | 000 0000 |
Neumora Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialNeumora Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Altitude Life Science Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Amgen | Corporation | Minority | 000 0000 | 000000 0 | |
| ARCH Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Catalio Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 |
Neumora Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 00 | 07-Oct-2021 | 0000000000 | Drug Discovery | 0000 0000 |